CoreWeave (CRWV.US) pre-performance: Oppenheimer sings more: data center capacity expansion exceeds expectations, 2026 revenue target may be significantly raised
Analysts have given CoreWeave a "outperform" rating with a target price of $150.
Investment bank Oppenheimer stated that, according to the latest research, the data center capacity expansion speed of CoreWeave (CRWV.US) seems to be faster than expected, which could drive revenue growth for this year.
Oppenheimer analyst Param Singh wrote in a report to clients, "CoreWeave is expected to release its first quarter earnings report on May 7th, and we anticipate its revenue to be at the higher end of the guidance range, with management likely to significantly increase its 2026 revenue target to above $12-13 billion (previously expected). This is based on the results of our industry survey, which indicate that CoreWeave's expansion speed has exceeded expectations and could potentially add 1 gigawatt capacity before the third quarter (above guidance/expectations). We also expect that the AI data center capacity shortage in the industry will continue for many years, and CoreWeave is likely to increase its capacity to at least 6 gigawatts during this period."
The analyst further noted that CoreWeave is expected to launch an additional 1 gigawatt capacity in the third quarter, which is higher than the full-year guidance target. Therefore, this should also imply potential revenue growth for this year. The analyst gave CoreWeave an "outperform" rating with a target price of $150, which represents about a 31% upside from the stock's closing price of $114.19 on Wednesday.
Related Articles

GENESIS SCALE (00439) granted a total of 12.31 million share purchase rights.

ICONCULTURE(08500): Further delay in the publication of the 2025 annual performance.

HANXBIO-B (03378) spent 440,100 Hong Kong dollars to repurchase 14,000 shares on April 30th.
GENESIS SCALE (00439) granted a total of 12.31 million share purchase rights.

ICONCULTURE(08500): Further delay in the publication of the 2025 annual performance.

HANXBIO-B (03378) spent 440,100 Hong Kong dollars to repurchase 14,000 shares on April 30th.

RECOMMEND





